PTC Therapeutics PTCT Noncash Interest Expense Liability Related To Sale Of Future Royalties

Noncash Interest Expense Liability Related To Sale Of Future Royalties at other companies

Ionis PharmaceuticalsIONS

$17.35M-6.2%

Kodiak Sciences IncKOD

$100M0.0%

GeronGERN

$20.69M+18.6%

GeronGERN

$20.69M+18.6%

Ultragenyx PharmaceuticalRARE

$1.13B+43.9%

Ultragenyx PharmaceuticalRARE

$1.13B+43.9%

FAQ

What is PTC Therapeutics's noncash interest expense liability related to sale of future royalties?

PTC Therapeutics (PTCT) reported noncash interest expense liability related to sale of future royalties of $65.7M in Q1 2026.

How has PTC Therapeutics's noncash interest expense liability related to sale of future royalties changed year-over-year?

PTC Therapeutics's noncash interest expense liability related to sale of future royalties increased by 32.3% year-over-year, from $49.66M to $65.7M.

What is the long-term trend for PTC Therapeutics's noncash interest expense liability related to sale of future royalties?

Over 4 years (2021 to 2025), PTC Therapeutics's noncash interest expense liability related to sale of future royalties has grown at a 29.0% compound annual growth rate (CAGR), from $77.68M to $215.16M.

What does noncash interest expense liability related to sale of future royalties mean?

Reflects the non-cash interest expense accrued on liabilities associated with the sale of future royalty rights. It accounts for the effective interest rate applied to the financing obligation over the life of the royalty agreement.